Medication info
Pelodis Tablet 10 mg (Memantine Hydrochloride)

Pelodis Tablet 10 mg (Memantine Hydrochloride)

Prescription medicationOrally disintegrating TabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
MYUNG IN PHARM.CO.,LTD.
Appearance
Flat round orally disintegrating tablet with bright pink speckled patterns and rounded edges
Packaging
30 tablets/PTP [15 tablets/PTP x 2], 90 tablets/PTP [15 tablets/PTP x 6]
Approval status
Active

MFDS item code 202007459 · Approved 2020.10.30 · Insurance code 651905010

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. This medicine is an orally disintegrating tablet; place it on the tongue and allow it to dissolve, then take it without water. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Day 1~7) Administer 5mg daily for 7 days. Week 2 (Day 8~14) Administer 10mg daily for 7 days. Week 3 (Day 15~21) Administer 15mg daily for 7 days. From week 4 onward Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose escalation method. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Importer
MYUNG IN PHARM.CO.,LTD.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease. It helps improve the patient's memory decline and cognitive function, contributing to the enhancement of daily living abilities. Through treatment, it assists in slowing the progression of symptoms and improving the quality of life.

How to take

Adult dose

This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. This medicine may be taken with or without food. This medicine is an orally disintegrating tablet; place it on the tongue and allow it to dissolve, then take it without water. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Day 1~7) Administer 5mg daily for 7 days. Week 2 (Day 8~14) Administer 10mg daily for 7 days. Week 3 (Day 15~21) Administer 15mg daily for 7 days. From week 4 onward Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose escalation method. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be administered to patients with phenylketonuria. As the artificial sweetener aspartame contained in this medication is broken down into phenylalanine in the body, it may pose a risk to individuals with hereditary diseases that restrict phenylalanine intake. Additionally, this medication should not be used in patients with hypersensitivity to it or those with severe liver or kidney dysfunction. In particular, it is contraindicated in cases of significantly reduced kidney function. Since this drug contains lactose, it should not be administered to patients with lactose intolerance or galactose metabolism disorders. Patients with epilepsy or a history of seizures should use this drug with caution, as the risk of side effects may increase when taken in conjunction with certain other medications, and co-administration should be avoided. Patients with heart disease or uncontrolled hypertension should also exercise caution when using this medication. This medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension, so it is advisable to consult healthcare professionals if any unusual symptoms occur. Since there may be interactions with other medications, it is essential to inform healthcare providers about any other medications being taken, particularly avoiding co-administration with NMDA receptor agonists. Women who are pregnant or may become pregnant should carefully weigh the risks and benefits of using this medication, and it is advisable to discontinue breastfeeding if nursing. This medication has not been confirmed to be safe and effective for children under 18 years of age; thus, it is recommended not to use it in this population. In the case of overdose, symptoms may include central nervous system symptoms or gastrointestinal symptoms, and immediate medical attention should be sought. This medication may affect the patient's reaction speed and concentration, so caution is needed when driving or operating machinery. Finally, store this medication out of reach of children, and avoid transferring it to other containers.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • drowsiness
  • confusion
  • hallucination
Show 34 more
  • psychotic reaction
  • dizziness
  • balance disorder
  • gait abnormality
  • seizure
  • heart failure
  • hypertension
  • venous thromboembolism
  • thromboembolism
  • dyspnea
  • constipation
  • vomiting
  • pancreatitis
  • elevated liver function test results
  • hepatitis
  • headache
  • fatigue
  • fatigue
  • weakness
  • diarrhea
  • confusion
  • drowsiness
  • anxiety
  • aggression
  • gait disturbance
  • vomiting
  • diarrhea
  • restlessness
  • psychosis
  • visual hallucination
  • convulsion
  • drowsiness
  • stupor
  • unconsciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, preferably at a cool temperature below 30 degrees Celsius. Storing it this way helps maintain its effectiveness.

Appearance and packaging

Appearance

Flat round orally disintegrating tablet with bright pink speckled patterns and rounded edges

Package unit

30 tablets/PTP [15 tablets/PTP x 2], 90 tablets/PTP [15 tablets/PTP x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.